Statistical properties of items and summary scores from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) in a diverse cancer sample Journal Article


Authors: Mead-Harvey, C.; Basch, E.; Rogak, L. J.; Langlais, B. T.; Thanarajasingam, G.; Ginos, B. F.; Lee, M. K.; Yee, C.; Mitchell, S. A.; Minasian, L. M.; Mendoza, T. R.; Bennett, A. V.; Schrag, D.; Dueck, A. C.; Mazza, G. L.
Article Title: Statistical properties of items and summary scores from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) in a diverse cancer sample
Abstract: Background/Aims: The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) was developed to capture symptomatic adverse events from the patient perspective. We aim to describe statistical properties of PRO-CTCAE items and summary scores and to provide evidence for recommendations regarding PRO-CTCAE administration and reporting. Methods: Using data from the PRO-CTCAE validation study (NCT02158637), prevalence, means, and standard deviations of PRO-CTCAE items, composite scores, and mean and maximum scores across attributes (frequency, severity, and/or interference) of symptomatic adverse events were calculated. For each adverse event, correlations and agreement between attributes, correlations between attributes and composite scores, and correlations between composite, mean, and maximum scores were estimated. Results: PRO-CTCAE items were completed by 899 patients with various cancer types. Most patients reported experiencing one or more adverse events, with the most prevalent being fatigue (87.7%), sad/unhappy feelings (66.0%), anxiety (63.6%), pain (63.2%), insomnia (61.8%), and dry mouth (60.0%). Attributes were moderately to strongly correlated within an adverse event (r = 0.53 to 0.77, all p < 0.001) but not fully concordant (κweighted = 0.26 to 0.60, all p < 0.001), with interference demonstrating lowest mean scores and prevalence among attributes of the same adverse event. Attributes were moderately to strongly correlated with composite scores (r = 0.67 to 0.97, all p < 0.001). Composite scores were moderately to strongly correlated with mean and maximum scores for the same adverse event (r = 0.69 to 0.94, all p < 0.001). Correlations between composite scores of different adverse events varied widely (r = 0.04 to 0.68) but were moderate to strong for conceptually related adverse events. Conclusions: Results provide evidence for PRO-CTCAE administration and reporting recommendations that the full complement of attributes be administered for each adverse event, and that attributes as well as summary scores be reported. © The Author(s) 2024.
Keywords: adult; controlled study; aged; middle aged; major clinical study; fatigue; antineoplastic agents; outcome assessment; antineoplastic agent; neoplasm; neoplasms; quality of life; pain; prevalence; health survey; validation study; questionnaire; disease severity; statistical analysis; anxiety; patient-reported outcomes; patient reported outcome measures; epidemiology; drug therapy; adverse drug reaction; symptoms; adverse event; adverse events; patient-reported outcome; tolerability; Common Terminology Criteria for Adverse Events; cancer; humans; human; male; female; article; drug-related side effects and adverse reactions; pro-ctcae<sup>®</sup>
Journal Title: Clinical Trials
Volume: 22
Issue: 2
ISSN: 1740-7745
Publisher: Sage Publications  
Date Published: 2025-04-01
Start Page: 161
End Page: 169
Language: English
DOI: 10.1177/17407745241286065
PUBMED: 39440720
PROVIDER: scopus
PMCID: PMC11986086
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Deborah Schrag
    229 Schrag